Esperion Therapeutics (NASDAQ:ESPR) Receives “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR) in a research report report published on Friday, Benzinga reports. HC Wainwright currently has a $16.00 price objective on the biopharmaceutical company’s stock.

Other equities research analysts have also recently issued research reports about the stock. Needham & Company LLC restated a buy rating and issued a $8.00 price objective on shares of Esperion Therapeutics in a research report on Tuesday, May 7th. Bank of America cut shares of Esperion Therapeutics from a neutral rating to an underperform rating and lowered their price target for the stock from $2.90 to $2.50 in a research report on Thursday, June 20th. Finally, StockNews.com cut shares of Esperion Therapeutics from a strong-buy rating to a buy rating in a research report on Friday, May 17th. One analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of Hold and a consensus price target of $8.83.

Esperion Therapeutics Stock Down 3.9 %

Shares of Esperion Therapeutics stock opened at $2.22 on Friday. The stock has a market capitalization of $420.60 million, a P/E ratio of -2.24 and a beta of 1.00. The company has a 50-day simple moving average of $2.31 and a 200 day simple moving average of $2.39. Esperion Therapeutics has a 12-month low of $0.70 and a 12-month high of $3.40.

Esperion Therapeutics (NASDAQ:ESPR) last announced its earnings results on Tuesday, May 7th. The biopharmaceutical company reported $0.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.42. The firm had revenue of $137.74 million for the quarter, compared to analyst estimates of $53.11 million. On average, equities analysts anticipate that Esperion Therapeutics will post -0.05 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Spire Wealth Management boosted its stake in Esperion Therapeutics by 69.2% during the 4th quarter. Spire Wealth Management now owns 17,767 shares of the biopharmaceutical company’s stock worth $53,000 after acquiring an additional 7,267 shares during the last quarter. Private Portfolio Partners LLC bought a new position in Esperion Therapeutics during the 4th quarter worth approximately $30,000. Herbst Group LLC bought a new position in Esperion Therapeutics in the first quarter valued at approximately $28,000. Summit Financial LLC lifted its stake in Esperion Therapeutics by 66.8% in the first quarter. Summit Financial LLC now owns 25,864 shares of the biopharmaceutical company’s stock valued at $69,000 after buying an additional 10,355 shares in the last quarter. Finally, PSI Advisors LLC lifted its stake in Esperion Therapeutics by 161.5% in the fourth quarter. PSI Advisors LLC now owns 17,000 shares of the biopharmaceutical company’s stock valued at $51,000 after buying an additional 10,500 shares in the last quarter. Institutional investors own 47.39% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.